Aid in dying wins approval if patient gives lethal dose

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 1
Volume 18
Issue 1

Oncology News International readers are on the whole in favor of “aid in dying” for terminally ill patients, but diff er on how it should be carried out.

Oncology News International readers are on the whole in favor of “aid in dying” for terminally ill patients, but diff er on how it should be carried out.

In 2008, Washington state passed an initiative that allows doctors to prescribe lethal prescriptions to terminally ill patients who have six months or less to live. The physician must also recommend, but not require, the patient to notify next of kin. The initiative is similar to Oregon’s 1998 Death With Dignity Act.

Of those who responded to the December poll question (“Do you agree with physician-assisted suicide?”), 24% said yes, if physicians determine survival time is less than six months.

Another 24% said yes, if the patient self administers the lethal dose of medication. Finally, 16% voted in favor of having the physician administer the lethal dose.

On the other hand, 16% said no because physician-assisted suicide validates euthanasia while another 16% voted no, not under any circumstances.

See page 2 and visit www.cancernetwork.com to register your vote on this month’s question, “Considering what we know now, should ESAs ever have been approved for chemotherapy-induced anemia?”

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content